EMA’s CHMP grants PRIME status to AbelZeta’s C-CAR168

Tuesday, July 21, 2026Salong DebbarmaView original

The EMA’s CHMP has granted PRIME designation to AbelZeta Pharma’s C-CAR168, an autologous anti-CD20/BCMA CAR-T therapy.

Read the full article on the original site.